MA32385B1 - Forme posologique pharmaceutique en capsule comprenant une formulation en suspension d'un derive d'indolinone - Google Patents
Forme posologique pharmaceutique en capsule comprenant une formulation en suspension d'un derive d'indolinoneInfo
- Publication number
- MA32385B1 MA32385B1 MA33402A MA33402A MA32385B1 MA 32385 B1 MA32385 B1 MA 32385B1 MA 33402 A MA33402 A MA 33402A MA 33402 A MA33402 A MA 33402A MA 32385 B1 MA32385 B1 MA 32385B1
- Authority
- MA
- Morocco
- Prior art keywords
- capsule
- dosage form
- pharmaceutical dosage
- suspension formulation
- indolinone derivative
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000002775 capsule Substances 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title 1
- 239000000725 suspension Substances 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne une formulation en suspension dont le principe actif est le 3-z-[1-(4- (n-((4-méthyl-pipérazin-1-yl)-méthylcarbonyl)-n-méthyl-amino)-anilino)-1-phényl-méthylène]-6- méthoxycarbonyl-2- indolinone-monoéthane-sulphonate. L'invention concerne également, d'une part une forme posologique pharmaceutique en capsule contenant ladite formulation en suspension, d'autre part un procédé d'élaboration de ladite formulation en suspension, mais aussi un procédé d'élaboration de ladite capsule comprenant ladite formulation en suspension, et également le matériau d'enveloppe de la capsule.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08157748 | 2008-06-06 | ||
| PCT/EP2009/056878 WO2009147212A1 (fr) | 2008-06-06 | 2009-06-04 | Forme posologique pharmaceutique en capsule comprenant une formulation en suspension d'un dérivé d'indolinone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA32385B1 true MA32385B1 (fr) | 2011-06-01 |
Family
ID=40911908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA33402A MA32385B1 (fr) | 2008-06-06 | 2010-12-06 | Forme posologique pharmaceutique en capsule comprenant une formulation en suspension d'un derive d'indolinone |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US20110301177A1 (fr) |
| EP (1) | EP2299987B1 (fr) |
| JP (2) | JP5661031B2 (fr) |
| KR (2) | KR20170020557A (fr) |
| CN (2) | CN105193720B (fr) |
| AR (1) | AR072059A1 (fr) |
| AU (1) | AU2009254548B2 (fr) |
| BR (1) | BRPI0913434B8 (fr) |
| CA (1) | CA2726267C (fr) |
| CL (1) | CL2010001279A1 (fr) |
| CO (1) | CO6280467A2 (fr) |
| CY (1) | CY1120533T1 (fr) |
| DK (1) | DK2299987T3 (fr) |
| EA (1) | EA029996B1 (fr) |
| EC (1) | ECSP10010660A (fr) |
| ES (1) | ES2669469T3 (fr) |
| HR (1) | HRP20180709T1 (fr) |
| HU (1) | HUE039187T2 (fr) |
| IL (1) | IL208954A (fr) |
| LT (1) | LT2299987T (fr) |
| MA (1) | MA32385B1 (fr) |
| MX (2) | MX2010013203A (fr) |
| MY (1) | MY158930A (fr) |
| NO (1) | NO2299987T3 (fr) |
| NZ (1) | NZ603162A (fr) |
| PE (1) | PE20100254A1 (fr) |
| PL (1) | PL2299987T3 (fr) |
| PT (1) | PT2299987T (fr) |
| RS (1) | RS57142B1 (fr) |
| SI (1) | SI2299987T1 (fr) |
| TW (1) | TW201002691A (fr) |
| UA (1) | UA104590C2 (fr) |
| UY (1) | UY31879A (fr) |
| WO (1) | WO2009147212A1 (fr) |
| ZA (1) | ZA201007636B (fr) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170065529A1 (en) | 2015-09-09 | 2017-03-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical dosage form for immediate release of an indolinone derivative |
| PL2299987T3 (pl) | 2008-06-06 | 2018-08-31 | Boehringer Ingelheim International Gmbh | Farmaceutyczna postać dawkowania w formie kapsułki zawierająca formulację zwiesiny pochodnej indolinonu |
| UA107560C2 (uk) * | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| AU2011260615B2 (en) * | 2010-06-02 | 2016-11-17 | Pharma& Schweiz Gmbh | Oral dosage forms of bendamustine |
| JO3659B1 (ar) * | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
| GB201020032D0 (en) * | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| US20140093498A1 (en) | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents |
| US20140350022A1 (en) | 2013-05-10 | 2014-11-27 | Boehringer Ingelheim International Gmbh | Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment |
| CA3280124A1 (en) | 2013-07-31 | 2025-10-31 | Avalyn Pharma Inc. | Aerosol imatinib compounds and uses thereof |
| US20150209360A1 (en) * | 2014-01-30 | 2015-07-30 | Orbz, Llc | Oral caffeine delivery composition |
| CN106031716B (zh) * | 2015-03-13 | 2022-04-15 | 江苏豪森药业集团有限公司 | 含有吲哚满酮衍生物混悬液的药物制剂及其制备方法 |
| CN108135737B (zh) | 2015-06-06 | 2021-11-05 | 拨云生物医药科技(广州)有限公司 | 用于治疗翼状胬肉的组合物和方法 |
| CN107019697A (zh) * | 2016-02-02 | 2017-08-08 | 瑞阳(苏州)生物科技有限公司 | 预防或治疗纤维化疾病的药物组合物及其应用 |
| BR112018074450A2 (pt) | 2016-06-02 | 2019-03-19 | Cloudbreak Therapeutics, Llc | composições e métodos para a utilização de nintedanib para melhorar o sucesso da cirurgia do glaucoma |
| US10561630B2 (en) * | 2016-10-25 | 2020-02-18 | Glykon Technologies Group, Llc | Hydroxycitric acid compounds and capsule liquid delivery |
| CN108066343A (zh) * | 2016-11-08 | 2018-05-25 | 瑞阳(苏州)生物科技有限公司 | 一种预防或治疗肾纤维化疾病的药物 |
| CN110062625A (zh) | 2016-12-12 | 2019-07-26 | 勃林格殷格翰国际有限公司 | 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法 |
| EP3600322A1 (fr) | 2017-03-28 | 2020-02-05 | Boehringer Ingelheim International GmbH | Nintedanib destiné à être utilisé dans des procédés de traitement de dystrophie musculaire |
| CN107184549B (zh) * | 2017-04-11 | 2020-11-20 | 江苏大学 | 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法 |
| LT3700529T (lt) | 2017-10-23 | 2025-10-10 | Naujas veikliųjų medžiagų derinys, skirtas progresuojančių fibrozinių intersticinių plaučių ligų (pf-ild) gydymui | |
| WO2019106692A1 (fr) * | 2017-11-29 | 2019-06-06 | Sun Pharmaceutical Industries Limited | Suspension orale de nintedanib esylate |
| CU24684B1 (es) | 2018-03-07 | 2023-10-06 | Pliant Therapeutics Inc | Compuestos de aminoácidos como inhibidores de la integrina |
| TWI787523B (zh) | 2018-06-15 | 2022-12-21 | 漢達生技醫藥股份有限公司 | 達沙替尼十二烷基硫酸鹽之結晶 |
| US12303504B2 (en) * | 2018-09-13 | 2025-05-20 | Oncosol Limited | Non-aqueous chemotherapeutic suspensions for oral dosage |
| WO2020079706A1 (fr) * | 2018-10-15 | 2020-04-23 | Cipla Limited | Formulation pharmaceutique |
| CN112386580B (zh) * | 2019-08-13 | 2022-07-08 | 齐鲁制药有限公司 | 具有改善的溶出度和稳定性的尼达尼布药物制剂、制备方法及其应用 |
| WO2021110805A1 (fr) | 2019-12-04 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combinaison d'un antagoniste du récepteur lpa1 de l'azétidine avec de la pirfénidone et/ou du nintedanib destinée à être utilisée dans le traitement de maladies fibrotiques |
| CN115361950A (zh) | 2020-04-01 | 2022-11-18 | 勃林格殷格翰国际有限公司 | 生物标记物在治疗纤维化病症中的用途 |
| EP4098246A1 (fr) | 2021-05-31 | 2022-12-07 | Lotus Pharmaceutical Co., Ltd. | Formulation de nintedanib |
| JP2024539645A (ja) * | 2021-10-14 | 2024-10-29 | プライアント・セラピューティクス・インコーポレイテッド | インテグリン阻害剤及び他の薬剤と組み合わせたその使用 |
| CN114404382B (zh) * | 2022-01-24 | 2023-05-12 | 南京康川济医药科技有限公司 | 乙磺酸尼达尼布软胶囊及其制备方法 |
| AU2022443590A1 (en) | 2022-02-28 | 2024-10-17 | Nuformix Technologies Limited | Compositions and methods for treatment of idiopathic pulmonary fibrosis |
| JP2025525881A (ja) | 2022-08-16 | 2025-08-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 眼内使用するためのニンテダニブの医薬製剤 |
| EP4389117A1 (fr) | 2022-12-19 | 2024-06-26 | Besins Healthcare Distribution FZ-LLC | Formulation de progestérone |
| US20250248971A1 (en) * | 2024-02-05 | 2025-08-07 | Anxo Pharmaceutical Co., Ltd. | Pharmaceutical composition and method using the same |
| KR102934107B1 (ko) | 2024-06-05 | 2026-03-06 | 영진약품 주식회사 | 닌테다닙 또는 이의 약학적으로 허용가능한 염을 포함하는 개선된 용출률을 갖는 신규한 정제 및 이의 제조방법 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2870062A (en) | 1956-04-27 | 1959-01-20 | Scherer Corp R P | Gelatin composition for capsules |
| GB8305693D0 (en) | 1983-03-02 | 1983-04-07 | Scherer Ltd R P | Pharmaceutical compositions |
| EP0169398B1 (fr) | 1984-07-24 | 1990-08-29 | R.P. Scherer GmbH | Gélules contenant du chlorhydrate d'oxytétracycline et procédé pour leur préparation |
| GB9313329D0 (en) * | 1993-06-28 | 1993-08-11 | Scherer Ltd R P | Softgel capsule shell compositions |
| DE19603402A1 (de) | 1995-02-24 | 1996-08-29 | Basf Ag | Weichgelatinekapseln |
| US6762180B1 (en) | 1999-10-13 | 2004-07-13 | Boehringer Ingelheim Pharma Kg | Substituted indolines which inhibit receptor tyrosine kinases |
| AP2003002900A0 (en) * | 2001-05-01 | 2003-12-31 | Pfizer Prod Inc | Method for manufacturing a low dose pharmaceutical composition |
| DE10233500A1 (de) * | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| US20060293260A1 (en) * | 2005-05-24 | 2006-12-28 | Wyeth | Useful high load concentrate compositions for control of ecto-and endo-parasites |
| CA2629249C (fr) | 2005-11-11 | 2015-05-05 | Boehringer Ingelheim International Gmbh | Traitement combine du cancer comprenant des inhibiteurs de egfr/her2 |
| PL2299987T3 (pl) | 2008-06-06 | 2018-08-31 | Boehringer Ingelheim International Gmbh | Farmaceutyczna postać dawkowania w formie kapsułki zawierająca formulację zwiesiny pochodnej indolinonu |
| UA107560C2 (uk) | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| MX338047B (es) * | 2008-06-06 | 2016-03-31 | Boehringer Ingelheim Int | Combinacion farmaceutica útil para el tratamiento fr enfermedades que involucran proliferación celular, migración o apoptosis de células de mieloma, angiogéneisis o fibrosis. |
| JP2012515184A (ja) | 2009-01-14 | 2012-07-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 大腸がんの治療方法 |
| US8802384B2 (en) * | 2009-03-12 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method or system using biomarkers for the monitoring of a treatment |
| EP2429520A1 (fr) | 2009-05-14 | 2012-03-21 | Boehringer Ingelheim International GmbH | Nouvelle polytherapie destinee a traiter les maladies oncologiques et fibrotiques |
-
2009
- 2009-06-04 PL PL09757593T patent/PL2299987T3/pl unknown
- 2009-06-04 CN CN201510660732.8A patent/CN105193720B/zh not_active Ceased
- 2009-06-04 PT PT97575930T patent/PT2299987T/pt unknown
- 2009-06-04 UA UAA201100098A patent/UA104590C2/ru unknown
- 2009-06-04 HR HRP20180709TT patent/HRP20180709T1/hr unknown
- 2009-06-04 DK DK09757593.0T patent/DK2299987T3/en active
- 2009-06-04 RS RS20180491A patent/RS57142B1/sr unknown
- 2009-06-04 MX MX2010013203A patent/MX2010013203A/es active IP Right Grant
- 2009-06-04 HU HUE09757593A patent/HUE039187T2/hu unknown
- 2009-06-04 PE PE2009000782A patent/PE20100254A1/es not_active Application Discontinuation
- 2009-06-04 LT LTEP09757593.0T patent/LT2299987T/lt unknown
- 2009-06-04 CN CN200980121067.8A patent/CN102056598B/zh not_active Ceased
- 2009-06-04 CA CA2726267A patent/CA2726267C/fr active Active
- 2009-06-04 JP JP2011512128A patent/JP5661031B2/ja active Active
- 2009-06-04 EP EP09757593.0A patent/EP2299987B1/fr active Active
- 2009-06-04 US US12/995,869 patent/US20110301177A1/en not_active Abandoned
- 2009-06-04 NZ NZ60316209A patent/NZ603162A/en unknown
- 2009-06-04 KR KR1020177004310A patent/KR20170020557A/ko not_active Withdrawn
- 2009-06-04 WO PCT/EP2009/056878 patent/WO2009147212A1/fr not_active Ceased
- 2009-06-04 MY MYPI2010005645A patent/MY158930A/en unknown
- 2009-06-04 KR KR1020107027317A patent/KR101725469B1/ko active Active
- 2009-06-04 MX MX2014006908A patent/MX359229B/es unknown
- 2009-06-04 BR BRPI0913434A patent/BRPI0913434B8/pt active IP Right Grant
- 2009-06-04 ES ES09757593.0T patent/ES2669469T3/es active Active
- 2009-06-04 NO NO09757593A patent/NO2299987T3/no unknown
- 2009-06-04 AU AU2009254548A patent/AU2009254548B2/en active Active
- 2009-06-04 SI SI200931833T patent/SI2299987T1/en unknown
- 2009-06-04 EA EA201001856A patent/EA029996B1/ru not_active IP Right Cessation
- 2009-06-05 AR ARP090102039A patent/AR072059A1/es unknown
- 2009-06-05 TW TW098118825A patent/TW201002691A/zh unknown
- 2009-06-08 UY UY0001031879A patent/UY31879A/es not_active Application Discontinuation
-
2010
- 2010-10-26 ZA ZA2010/07636A patent/ZA201007636B/en unknown
- 2010-10-26 IL IL208954A patent/IL208954A/en active IP Right Grant
- 2010-11-22 CL CL2010001279A patent/CL2010001279A1/es unknown
- 2010-12-03 EC EC2010010660A patent/ECSP10010660A/es unknown
- 2010-12-03 CO CO10152519A patent/CO6280467A2/es not_active Application Discontinuation
- 2010-12-06 MA MA33402A patent/MA32385B1/fr unknown
-
2013
- 2013-08-30 US US14/015,186 patent/US20140004187A1/en not_active Abandoned
-
2014
- 2014-08-11 JP JP2014163667A patent/JP5905542B2/ja active Active
-
2015
- 2015-10-07 US US14/877,132 patent/US20160022672A1/en not_active Abandoned
-
2016
- 2016-07-07 US US15/204,277 patent/US9907756B2/en active Active
-
2018
- 2018-05-15 CY CY20181100499T patent/CY1120533T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015003653A (es) | Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj. | |
| EA201590118A1 (ru) | Производные пирролидина и их применение в качестве модуляторов пути активации комплемента | |
| BR112015000578A2 (pt) | moduladores da via do complemento e usos dos mesmos | |
| MX359988B (es) | Derivado de pirazol y uso del mismo para propósitos médicos. | |
| UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
| HRP20180709T1 (hr) | Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinona | |
| EA201290654A1 (ru) | Новые замещенные триазольные производные как модуляторы гамма-секретазы | |
| UA109421C2 (uk) | Фармацевтична композиція, яка містить ліганди сигма-рецептора | |
| NO20092535L (no) | Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol | |
| EA201171363A1 (ru) | Новые замещенные производные индазола и азаиндазола в качестве модуляторов гамма-секретазы | |
| MA39088A1 (fr) | Compositions et procédés pour moduler des récepteurs farnesoïde x | |
| EA201101671A1 (ru) | Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина | |
| CU23914B1 (es) | DERIVADOS DE 2-(1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL/2-OXOIMIDAZOLIDIN-1-IL)PIRIDIN-4-CARBOXAMIDA ACTIVOS COMO MODULADORES DE ESTEAROIL CoA | |
| EA201201050A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| IN2014MN00258A (fr) | ||
| EA201170829A1 (ru) | Замещенные бициклические производные имидазола в качестве модуляторов гамма-секретазы | |
| MA32386B1 (fr) | Forme posologique pharmaceutique pour libération immédiate de dérivé d'indolinone | |
| MX394108B (es) | Derivados de indol n-sustituidos. | |
| EA201400067A1 (ru) | Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента | |
| MA38854B1 (fr) | Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique | |
| CR20110704A (es) | Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amilodipina, su preparación y su aplicación terapéutica | |
| EA200801184A1 (ru) | Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2 | |
| UA110979C2 (uk) | Рідка фармацевтична композиція, яка включає нітизинон | |
| AR073265A1 (es) | Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio | |
| MA38679B1 (fr) | Modulateurs du récepteur de cxcr7 |